ClinicalTrials.gg
Status unknownNCT03651115MIDOMENUpdated Aug 29, 2018

TDM of Gentamicin and Vancomycin, in Neonates, Using Dried Blood Spot Sampling.

An observational study in Blood Sample for Routine Care, Term or Premature Newborns (28 to 44 Amenorrhea Weeks) and Gentamicin and/or Vancomycin, sponsored by University Hospital, Caen. Status unknown at 1 site in France. Open to participants aged 28 Weeks to 44 Years. Per ClinicalTrials.gov, last updated 2018-08-29.

Sponsored by University Hospital, Caen · Observational

How we know

The sponsor has not verified this record recently (last verified Jul 2018), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
100
Ages
28 Weeks to 44 Years
Sex
All
01

Study summary

Gentamicin and vancomycin, widely used in neonatology, are antibiotics with a narrow therapeutic index and a risk of nephrotoxicity and ototoxicity. For these drugs, therapeutic drug monitoring (TDM) is required, to optimize the efficacy and tolerance of these antibiotics.

In newborns, the TDM of these antibiotics is really available, because of physiological features, such as renal elimination and hepatic metabolism which are both very dependent on age and maturation. Thus, in newborn, there is a large interindividual variability of pharmacokinetic parameters, making the dosage adjustment of antibiotics very difficult.

Unfortunately, because of a limited blood mass, the TDM of these antibiotics is very rarely practiced in these children. The introduction of a Died blood spot (DBS), which uses only a single drop of blood (\<50 μL) preserved in dried form, thus makes it possible to reduce the blood volume taken and avoid the venous intrusion. The dosage needs the use of liquid chromatography coupled with tandem mass spectrometry (LC-MSMS), the only sensitive technique to work with such a low blood volume.

We therefore wish to develop this approach coupling DBS and LC-MSMS, in neonatology, to evaluate the concentration of these nephrotoxic antibiotics (gentamicin and vancomycin), as TDM. The blood concentrations of the antibiotic, per 100 new-born term or premature (50 gentamicin, 50 vancomycin), are compared to the physiological state of the child (premature or not, intrauterine growth retardation or not), its hemodynamic status (shock or not) and its efficacy / toxicity, evaluated by the clinician using a questionnaire.

The use of this new sampling method, as an alternative to conventional blood sampling, makes it possible to better monitor the concentrations of gentamicin and vancomycin in neonatalogy, thus reducing the risk of toxicity of these antibiotics.

02

Conditions studied

  • Blood Sample for Routine Care
  • Term or Premature Newborns (28 to 44 Amenorrhea Weeks)
  • Gentamicin and/or Vancomycin

Browse trials for

03

In context

Amenorrhea

80 studies on the registry are indexed under Amenorrhea; 17 are open to participants now.

This study's planned enrollment of 100 is above the median of 85 across 26 observational studies indexed under Amenorrhea.

Browse Amenorrhea studies →

Lead sponsor

University Hospital, Caen is the lead sponsor of 515 studies on the registry; 84 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
28 Weeks to 44 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

100 new-born term or premature (50 gentamicin, 50 vancomycin)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Term or premature newborns who receive one or two antibiotics (gentamicin, vancomycin) and who could benefit from pharmacological dosages of these drugs
  • Premature from age 28 amenorrhea weeks
  • Newborns up to 44 weeks corrected age
  • Newborns at term / premature having a blood sample provided for routine care (capillary or venous sampling for blood glucose, blood gas, hemoglobinemia, sodium, potassium, lactate, )

Exclusion criteria

Exclusion Criteria:

  • Premature before age 28 amenorrhea weeks corrected
  • Newborns over 44 weeks of age corrected
  • Hemostasis disorders
  • Hemoglobinopathies
  • Hearing or kidney malformation
  • Absence of blood sampling as part of the routine care
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Neonates with gentamicin

    Diagnostic Test: therapeutic drug monitoring

  • Neonates with vancomycin

    Diagnostic Test: therapeutic drug monitoring

Interventions

  • Diagnostic testtherapeutic drug monitoring

    To monitor the blood concentrations of gentamicin and vancomycin

06

What researchers measure

Primary outcomes

  1. Sampling time for vancomycin concentration

    Time frame: Day 3

  2. Sampling time for gentamycin concentration

    Time frame: Day 2

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2017 (actual). Primary completion is estimated for Sep 2019, 21 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2018
First posted
Aug 29, 2018
StartActual
Dec 15, 2017
Primary completionEst.
Sep 2019
CompletionEst.
Sep 2019
Last update
Aug 29, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03651115
Responsible party
Sponsor
First posted
Aug 29, 2018
Start date
Dec 15, 2017
Primary completion
Sep 2019 (estimated)
Completion
Sep 2019 (estimated)
Last update
Aug 29, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion